Drug Trial Radar · NCT02825836
Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects
Last checked: Nov 19, 2026Latest source record: Jul 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
130
Planned (sponsor's estimate)
Start
Aug 26, 2016
Primary completion
Dec 1, 2024
Study completion Dec 1, 2025
Sponsor
- Lead sponsor
- Telios Pharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 7, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this research study is to determine the safety and tolerability of TL-895. There are 2 parts of this study. Part 1 tested increasing doses of TL-895 to identify the recommended safe dose for participants with relapsed/refractory (R/R) B cell malignancies who failed at least 1 but no more than 3 prior therapies. Part 1 of this study is no longer enrolling participants. Arms 1 \& 2 of Part 2 of this study will test different doses of TL-895 in participants with R/R CLL or SLL who have failed at least 1 prior therapy. Arms 1 \& 2 of Part 2 of this study is randomized (like the flip of a coin) to receive a specific treatment dose. If someone participates in arms 1 or 2 of Part 2, the dose they receive will be either 100mg twice a day or 150mg twice a day. Arms 3 and 4 of Part 2 of this study will test the 150mg and 100mg BID dose of TL-895, respectively in treatment naïve participants with CLL/SLL. Arms 5 and 6 of Part 2 will test 150mg TL-895 BID in combination with 240 mg navtemadlin QD in participants with relapsed/refractory and treatment naïve without 17p(del). Arm 7 will test 150mg TL-895 in combination with 240 mg navtemadlin QD in participants with relapsed/refractory CLL/SLL with 17p(del). Every participant in this study will receive TL-895.
Conditions
- Relapsed/Refractory B Cell Malignancies
- Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Treatment-Naive B Cell Malignancies
Interventions
TL-895Drug
TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.
NavtemadlinDrug
Navtemadlin is an experimental MDM2 anticancer drug taken by mouth.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 (Dose Escalation): DLTs (Dose Limiting Toxicities) during Cycle 1Time frame: Baseline up to the end of cycle 1 (28 days)
- Part 2 (Dose Expansion): Overall Response Rate (ORR)Time frame: Baseline up to end of study (2 years after last patient enrolled)
Locations
17 sites in 7 countries. Site status is shown where the registry gives one.
Ohio State University Wexner Medical Center
Columbus, Ohio
The West Clinic
Germantown, Tennessee
Debreceni Egyetem - Borgyógyászati Klinika
Debrecen, Hungary
Eger Markhot Ferenc Kórház
Eger, Hungary
Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi - Istituto di Ematologia e Oncologia Medica
Bologna, Italy
Pratia MCM Krakow
Krakow, Poland
Centrum Onkologii Ziemi Lubelskiej im sw Jana z Dukli Oddzial Hematologiczny
Lublin, Poland
Szpital Wojewódzki
Opole, Poland
Nasz Lekarz Przychodnie Medyczne
Torun, Poland
Examen sp. z o. o.
Skorzewo, Poznań, Poland
Saint Petersburg State Medical University
Saint Petersburg, Russia
Yaroslavl Regional Clinical Hospital
Yaroslavl, Russia
Communal Non-profit Enterprise Regional Center of Oncology
Kharkiv, Ukraine
Kyiv City Clinical Hospital #4
Kyiv, Ukraine
Mykolaiv Regional Clinical Hospital
Mykolaiv, Ukraine
University College London Hospitals - NIHR/Wellcome Trust
London, United Kingdom
Derriford Hospital - Dept of Haematology
Plymouth, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.